NanoString Technologies Releases Operating Results for First Quarter of 2022

May 10, 2022

SEATTLE–(BUSINESS WIRE)– NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the first quarter ended March 31, 2022.

First Quarter Financial Highlights

  • Product and service revenue of $30.8 million
  • GeoMx® Digital Spatial Profiler (DSP) revenue of $9.7 million. GeoMx DSP revenue includes:
    • Instrument revenue of $4.8 million, 31% year-over-year decline
    • Consumables revenue of $4.9 million, 78% year-over-year growth, annualized pull-through of approximately $76,000 per installed system
  • nCounter® revenue, inclusive of all service revenue, of $21.1 million. nCounter revenue includes:
    • Instrument revenue of $4.3 million, 11% year-over-year decline
    • Consumables revenue of $12.6 million, 5% year-over-year decline, annualized pull-through of approximately $48,000 per installed system
    • Service revenue of $4.3 million, 16% year-over-year growth
  • Cash, cash equivalents and short-term investments balance of $312.1 million

“We have begun to address the challenges we experienced in the first quarter, and we believe we have the sales team and commercial structure in place to execute our long-term growth strategy” said Brad Gray, president & CEO of NanoString. “Overall growth and customer interest in spatial biology remains robust, as evidenced by the strong demand for CosMx SMI that we experienced during the first quarter.”

Operational Highlights

GeoMx DSP

  • GeoMx Installed Base:
    Grew installed base to approximately 295 GeoMx DSP Systems at March 31, 2022, representing 84% growth over the prior year
  • Workflow Automation:
    Partnered with Leica, a division of Danaher, to provide a fully automated workflow for using the Leica Bond RX system to prepare slides for GeoMx DSP
  • American Association of Cancer Research
    : Highlighted a record body of more than 120 Nanostring-enabled abstracts, including more than 35 abstracts focused on spatial biology
  • Publications:
    Continued growth of peer-reviewed publications utilizing GeoMx DSP technology, with approximately 20 new publications in the first quarter, bringing the cumulative total to approximately 110 peer-reviewed publications as of March 31, 2022

CosMx SMI

  • CosMx Orders:
    Secured customer orders for more than 15 CosMx™ Spatial Molecular Imager (SMI) systems, bringing total orders to date to more than 35 systems
  • Development Status:
    First CosMx beta systems placements expected during the second quarter and the program remains on track for full commercial launch in the fourth quarter of 2022.

nCounter

  • nCounter Installed Base:
    Grew installed base to approximately 1,070 nCounter Analysis Systems at March 31, 2022, representing 8% growth over the prior year
  • nCounter Pro Analysis System Launch:
    Launched the nCounter Pro Analysis System, the next generation of the nCounter instrument platform, which includes a new operating system, modern cybersecurity improvements and an expansive menu to support biomanufacturing and translational research
  • Publications:
    Surpassed 5,250 cumulative peer-reviewed publications utilizing nCounter technology at March 31, 2022

Corporate

  • Appointment of New Board Member:
    Expanded the Board of Directors with the appointment of Dr. Teresa Foy, senior vice president, Immuno-Oncology and Cell Therapy, Bristol Myers Squibb

2022 Outlook

The company updated its 2022 outlook, with results expected as follows:

  • Total product and service revenue of $150 to $160 million, as compared to previous guidance of $170 to $180 million
    • GeoMx DSP revenue of $60 to $65 million, as compared to previous guidance of $73 to $78 million
    • nCounter revenue, inclusive of all service revenue, of $90 to $95 million, as compared to previous guidance of $97 to $102 million
  • Adjusted EBITDA loss of $65 to $75 million, as compared to previous guidance of $55 to $65 million

Financial Results

We have elected to present selected non-GAAP, or adjusted, financial measures, including Adjusted EBITDA. These adjusted financial measures are calculated excluding certain items that may make it more challenging to compare our GAAP operating results across periods. Such items may include collaboration revenue, stock-based compensation, depreciation and amortization, or one-time charges such as transaction related fees and expenses or restructuring charges and severance costs. A reconciliation of adjusted financial measures to the nearest comparable GAAP financial measure can be found in the notes and table at the end of this press release.

(dollars in thousands)

Three Months Ended March 31,

GAAP

Non-GAAP Adjusted

2022

2021

2022

2021

Product and service revenue

$

30,841

$

31,394

$

30,841

$

31,394

Collaboration revenue

239

223

Total revenue

31,080

31,617

30,841

31,394

Cost of product and service revenue

14,778

15,623

13,789

15,027

Research and development

17,417

15,063

14,956

12,573

Selling, general and administrative

36,355

26,799

29,397

20,958

Adjusted EBITDA

N / A

N / A

$

(27,301

)

$

(17,164

)

Non-operating expense, net

(2,030

)

(1,844

)

(2,030

)

(1,844

)

Net loss

$

(39,500

)

$

(27,712

)

$

(29,331

)

$

(19,008

)

Supplemental Information

As a supplement to the table above, we have posted to the investor relations section of our website, at www.nanostring.com/Investor Relations/Financials/Quarterly Results, supplemental financial data that include our adjusted financial measures as compared to the nearest comparable GAAP financial measures, for the first quarter of 2022 and for each quarter and the full year of 2021.

Conference Call

Management will host a conference call today beginning at 1:30 pm PT / 4:30 pm ET to discuss these results and answer questions. Investors and other interested parties can register for the call in advance by visiting https://www.incommglobalevents.com/registration/q4inc/10798/nanostring-first-quarter-2022-operating-results/. After registering, an email confirmation will be sent including dial-in details and unique conference call codes for entry. Registration is open throughout the call, but to ensure connection for the full call, registration in advance is recommended. The link to the webcast and audio replay will be made available at the Investor Relations website: www.nanostring.com. A replay of the call will be available beginning May 10, 2022 at 7:30pm ET through midnight ET on May 17, 2022. To access the replay, dial (866) 813-9403 or (929) 458-6194 and reference Conference ID: 221442. The webcast will also be available on our website for one year following the completion of the call.

Non-GAAP, or Adjusted, Financial Information

We believe that the presentation of non-GAAP, or adjusted, financial information provides important supplemental information to management and investors regarding financial and business trends relating to our financial condition and results of operations. Reconciliation of adjusted financial measures to the most directly comparable financial result as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. A reconciliation of adjusted guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding certain expenses that may be incurred in the future. For further information regarding why we believe that these adjusted measures provide useful information to investors, the specific manner in which management uses these measures and some of the limitations associated with the use of these measures, please refer to “Notes Regarding Non-GAAP Financial Information” at the end of this press release.

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company provides three platforms that allow researchers to map the universe of biology. The nCounter® Analysis System, cited in more than 5,250 peer-reviewed publications, offers a way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. NanoString’s GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections, and has been cited in approximately 110 peer-reviewed publications. The CosMx™ Spatial Molecular Imager, with commercial availability expected in 2022, enables highly sensitive, high-resolution imaging of hundreds to thousands of RNAs or proteins directly from single cells within morphologically intact whole tissue sections. For more information, visit www.nanostring.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding expectations for demand for our products and growth in our business, our efforts to address sales challenges experienced in first quarter, future revenue growth, the impact of the COVID-19 pandemic on our operations and future financial performance, the impact of new products and expansion into new markets, the growth trajectory of our nCounter, GeoMx and CosMx franchises, the anticipated launch of new products and technology and our estimated 2022 operating results and our anticipated GAAP and non-GAAP operating results. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; the extent and duration of the impact of the COVID-19 pandemic and adverse conditions in the general domestic and global economic markets; the effects of ongoing litigation; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing and product development; as well as the other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.

The NanoString logo, NanoString, NanoString Technologies, GeoMx, CosMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc., in the United States and/or other countries.

NANOSTRING TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended

March 31,

2022

2021

Revenue:

Instruments

$

9,103

$

11,745

Consumables

17,468

15,963

Services

4,270

3,686

Total product and service revenue

30,841

31,394

Collaboration

239

223

Total revenue

31,080

31,617

Costs and expenses:

Cost of product and service revenue

14,778

15,623

Research and development

17,417

15,063

Selling, general and administrative

36,355

26,799

Total costs and expenses (a) (b)

68,550

57,485

Loss from operations

(37,470

)

(25,868

)

Other income (expense):

Interest income

151

118

Interest expense

(1,883

)

(1,870

)

Other income expense, net

(217

)

(32

)

Total other expense, net

(1,949

)

(1,784

)

Net loss before provision for income taxes

(39,419

)

(27,652

)

Provision for income taxes

(81

)

(60

)

Net loss

$

(39,500

)

$

(27,712

)

Net loss per share, basic and diluted

$

(0.86

)

$

(0.62

)

Weighted average shares used in computing basic and diluted net loss per share

45,998

44,669

(a) Includes $7.7 million and $7.4 million of stock-based compensation expense for the three months ended March 31, 2022 and 2021, respectively.

(b) Includes $1.5 million and $1.4 million of depreciation and amortization expense for the three months ended March 31, 2022 and 2021, respectively.

NANOSTRING TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

March 31,

2022

December 31,

2021

Assets

Current assets:

Cash and cash equivalents

$

98,457

$

107,068

Short-term investments

213,618

241,821

Accounts receivable, net

30,381